Does Humana Cover Vardenafil (Levitra/Staxyn)?

Humana Commercial Formulary Placement for Vardenafil

Generic vardenafil sits on Tier 3 (preferred brand) or Tier 4 (non-preferred) of most Humana commercial formularies, depending on the specific plan document. A Tier 3 placement means a copay between $35 and $75 per fill. Tier 4 shifts that cost to a coinsurance model, often 25% to 50% of the negotiated price.

Brand-name Levitra lost U.S. patent exclusivity in 2018, and Humana moved most enrollees toward the generic. The orally disintegrating tablet (Staxyn) is no longer actively marketed domestically, so formulary listings for that product are largely academic. If your plan still references Staxyn, expect non-formulary status and a coverage exception request.

Humana updates its formulary quarterly. The January and July refreshes are the most common points where tier placement shifts. You can verify your specific plan's current tier by logging into MyHumana or calling the number on the back of your member ID card. Porst et al. demonstrated vardenafil 10 mg and 20 mg produced statistically significant improvements in erectile function (IIEF-EF domain scores increased by 5.9 and 6.8 points above placebo, P<0.001) in a randomized trial of 580 men with ED of broad etiology 1.

Medicare Advantage: Why Most Humana MA Plans Exclude ED Drugs

The Centers for Medicare & Medicaid Services (CMS) classifies erectile dysfunction medications as a "Part D exclusion" category. This means Medicare Part D plans are not required to cover them, and most choose not to. Humana's Medicare Advantage Prescription Drug (MAPD) plans follow this rule almost universally.

This is not a Humana-specific policy. It is a federal coverage determination. The Social Security Act §1860D-2(e)(2)(A) lists ED agents among drugs that Part D sponsors may exclude. Humana's 2025 and 2026 Annual Notice of Changes (ANOC) documents for MAPD plans confirm this exclusion in the formulary appendix.

If you are a Humana MA enrollee and your prescriber believes vardenafil is medically necessary for a condition other than ED (for example, pulmonary arterial hypertension, though sildenafil and tadalafil are standard for PAH), a coverage exception request citing clinical necessity is theoretically possible. Approval rates are low. The American Urological Association (AUA) 2018 guidelines on ED management note that PDE5 inhibitors remain first-line pharmacotherapy for erectile dysfunction 2, yet this guideline endorsement does not override the CMS Part D exclusion.

Prior Authorization Requirements

Humana commercial plans that do cover vardenafil typically require prior authorization (PA). The PA criteria generally include:

A documented diagnosis of erectile dysfunction (ICD-10 code N52.x). A prescriber attestation that the condition has an organic or mixed etiology. Confirmation the patient is 18 years or older. No concurrent nitrate therapy (an absolute contraindication per the FDA-approved labeling). Trial and failure, intolerance, or contraindication to at least one lower-cost PDE5 inhibitor, usually sildenafil.

PA turnaround for non-urgent requests is 5 to 15 business days on Humana commercial lines. Urgent (expedited) PA decisions arrive within 72 hours. Your prescriber's office submits the PA through Humana's CoverMyMeds portal or by fax.

The FDA-approved prescribing information for vardenafil specifies contraindications including concurrent organic nitrates and alpha-blockers at doses above a threshold, which the PA reviewer will cross-reference 3.

Step Therapy: What You Must Try First

Step therapy is Humana's requirement that you trial a first-line, lower-cost medication before the plan will approve a second-line option. For PDE5 inhibitors, Humana's step-therapy protocol almost always requires a documented trial of generic sildenafil (25 mg, 50 mg, or 100 mg) lasting at least 4 to 6 attempts on separate occasions.

Some plans accept generic tadalafil as the step-therapy agent instead of sildenafil, or accept failure of either one. "Failure" means inadequate efficacy at the maximum tolerated dose, intolerable side effects (headache, flushing, visual disturbance, myalgia), or a documented drug interaction that precludes use.

Why does step therapy exist? Sildenafil costs Humana's pharmacy benefit approximately $0.50 to $3.00 per tablet at contracted rates. Generic vardenafil costs $8 to $15 per tablet. The plan captures meaningful per-member savings by routing patients through the cheaper agent first.

If sildenafil caused unacceptable flushing or headache, your prescriber documents this in the step-therapy override request. A 2011 meta-analysis comparing PDE5 inhibitors found vardenafil's selectivity for PDE5 over PDE6 was greater than sildenafil's, which may explain fewer visual side effects in some patients 4.

How to Appeal a Humana Denial of Vardenafil

A denial is not the end. Humana provides a structured appeals process.

Internal Appeal (Level 1). You or your prescriber submit a written appeal within 60 days of the denial letter (180 days for Medicare Advantage). Include: the denial reference number, clinical notes supporting medical necessity, relevant lab work (testosterone levels if hypogonadism is a contributing factor), and documentation of step-therapy failure. Humana must respond within 30 calendar days for standard requests, 72 hours for expedited.

Internal Appeal (Level 2, commercial only). If Level 1 is upheld, commercial members can request a second internal review by a different medical director.

External Review. Commercial members in most states can request an Independent Review Organization (IRO) evaluation after exhausting internal appeals. Medicare Advantage members access external review through the MAXIMUS Federal Services contractor, which handles Part C reconsiderations on a 60-day timeline.

Data from CMS show that approximately 44% of Part C appeals overturned at the first level of external review in 2023 5. This means nearly half of denials that reach MAXIMUS are reversed. The effort of filing is often worthwhile.

Key documentation to strengthen an appeal: AUA guideline citations confirming PDE5 inhibitors as first-line therapy, evidence of step-therapy failure, any cardiovascular contraindication to alternative agents, and patient-reported outcome scores (IIEF-5 or SHIM questionnaire).

Quantity Limits and Dosing Restrictions

Humana imposes quantity limits (QL) on all PDE5 inhibitors, including vardenafil. The standard limit is 6 tablets per 30-day supply for most commercial plans. Some Humana employer-sponsored plans allow up to 12 tablets per month.

Vardenafil is FDA-approved at 5 mg, 10 mg, and 20 mg doses taken as needed, approximately 60 minutes before sexual activity, with a maximum of one dose per 24-hour period 3. The quantity limit aligns with a presumed dosing frequency of 1 to 2 times per week. If your prescriber documents a clinical rationale for more frequent dosing (for example, a penile rehabilitation protocol post-radical prostatectomy), a quantity limit exception can be requested through the PA process.

The Porst et al. trial used flexible dosing (5, 10, or 20 mg) and found that 85% of patients achieved successful intercourse on 20 mg versus 49% on placebo (P<0.001), supporting the maximum dose as effective for the majority of men with moderate-to-severe ED 1.

Using Manufacturer Savings Cards with Humana

Brand-name Levitra manufacturer coupons and savings cards do exist but carry restrictions. Most savings cards explicitly exclude government-funded insurance (Medicare, Medicaid, Tricare, VA). For Humana commercial members, a savings card can reduce out-of-pocket cost at the pharmacy counter, but the card's value does not count toward your plan deductible or out-of-pocket maximum under the Affordable Care Act's accumulator adjustment programs.

Check whether your Humana plan uses a copay accumulator or copay maximizer program. If it does, the savings card pays your copay, but the plan does not credit that amount toward your annual deductible. You could face full-price exposure later in the plan year when the card's annual cap is reached.

For generic vardenafil, manufacturer savings cards are generally unavailable because multiple generic manufacturers produce the tablet. GoodRx, RxSaver, and similar discount programs show cash prices between $15 and $45 for six generic vardenafil 20 mg tablets at major retail pharmacies as of May 2026.

Cost Comparison: Insurance vs. Cash Pay

Understanding your true cost with and without Humana coverage helps you make a pragmatic decision.

With Humana commercial Tier 3 coverage and a $50 copay, six tablets per month cost $50 out of pocket. With Tier 4 coinsurance at 40% and a negotiated price of $90, you pay $36. Without insurance, the GoodRx price for 6 tablets of generic vardenafil 20 mg averages $20 to $45 at retail chains.

In many cases, cash-pay generic pricing beats the insured copay. This is worth calculating before investing time in prior authorization and step-therapy documentation. If your out-of-pocket cost through insurance exceeds cash-pay pricing, you may choose to fill outside your benefit, though this spend will not count toward your deductible.

Brand Levitra remains expensive. The WAC (wholesale acquisition cost) is approximately $350 for a 30-day supply. Few patients have a clinical reason to use brand over generic. Bioequivalence was established during the FDA's abbreviated new drug application (ANDA) review process for generic vardenafil, meaning the generic delivers the same plasma concentration profile (Cmax and AUC within 80% to 125% of the reference product) 3.

Vardenafil vs. Other PDE5 Inhibitors on Humana Formularies

Humana's formulary generally places generic sildenafil at the lowest tier (Tier 1 or 2), generic tadalafil at Tier 2 or 3, and generic vardenafil at Tier 3 or 4. This hierarchy reflects negotiated rebate volume and market share rather than clinical superiority.

A network meta-analysis of 82 randomized trials (N=47,626) published in the Journal of Sexual Medicine found no statistically significant difference in overall efficacy among sildenafil, tadalafil, and vardenafil for ED treatment 6. Differences are pharmacokinetic: vardenafil's onset is 25 to 60 minutes with a half-life of 4 to 5 hours, tadalafil's half-life extends to 17.5 hours, and sildenafil's half-life is 3 to 5 hours. Patient preference, dosing flexibility, and side-effect profile drive clinical selection.

If your Humana plan denies vardenafil on step-therapy grounds but you have a documented clinical reason to prefer it (for example, tadalafil caused back pain and sildenafil caused visual disturbance), that documentation supports your exception request.

Tips for Getting Vardenafil Approved on Humana

Work with your prescriber to pre-empt the most common denial reasons.

Document sildenafil failure in the medical record before prescribing vardenafil. Include dates, doses tried, and specific adverse effects or lack of efficacy. Use ICD-10 code N52.01 (erectile dysfunction due to arterial insufficiency) or the appropriate subcode rather than the nonspecific N52.9. Attach a completed IIEF-5 questionnaire showing moderate or severe ED (score <17). Submit PA proactively rather than waiting for a pharmacy rejection to trigger the process.

If testosterone is low (total T <300 ng/dL), document this as well. The Endocrine Society's 2018 guideline recommends treating underlying hypogonadism concurrently with PDE5 inhibitor therapy for men with both conditions 7. Co-management of hormonal and vascular contributions strengthens the medical-necessity argument.